Skip to main content
. 2022 Jan 3;22:2. doi: 10.1186/s12935-021-02407-8

Table 3.

ICI combination therapy with CXCR4 blockade in cancer therapy

Tumor Target IC Result References
Hepatocellular carcinoma PD-1 Inhibition of tumor growth and lung metastasis along with improved OS rate in mice models [231]
Triple-negative breast cancer PD-L1 Robust antitumor effect and extended OS rate in 4T1 cell bearing murine model [235]
Ovarian cancer PD-1

Enhancing the effector T-cell infiltration, improving effector T-cell function and also memory T cells in TME

Reducing intratumoral Treg cells and promoting the conversion of Treg cells into T helper

Improved OS rate in mice model

[233]
Glioblastoma PD-1

Improving the memory T cells and reducing MDSCs

Promoting CD4 + /CD8 + ratios in the brain and elevation of pro-inflammatory cytokines levels in the brain

[36]
Pancreatic ductal adenocarcinoma PD-1 Inspiring the CD8 + T-cell migration into the juxtatumoral compartment and also induction apoptosis in tumor cell [237]
Osteosarcoma PD-1 Inducing tumor regression by suppressing MDSCs in mice model [232]

Colon cancer

Melanoma

PD-1 Inhibition of tumor growth in two syngeneic murine models, by improving granzyme and suppressing FOXP3 cells infiltration [236]
Ovarian cancer PD-1 Improved OS rate in treated mice model [234]
Lung cancer PD-L1

Improving the T cell infiltration, enhancing expression of calreticulin on tumor cells

Reducing MDSCs and Treg in the TME

[274]
Glioblastoma PD-1

Demonstrating immune memory concurrently reducing populations of MDSCs and tumor-promoting immune cells

Improved OS rate in treated mice model

[275]
Triple-negative breast cancer PD-L1 Promoting the tumor immunogenicity to recruit T cells, attenuating the physiological barricades of intratumoral fibrosis and collagen to support T cell infiltration, and reducing the immunosuppressive cells to revive T cells [276]
Melanoma PD-1 Modulating the immune cell profile within the TME and improving CD8 + T cell infiltration [277]

ICI immune checkpoint inhibitor, PD-1 programmed cell death protein 1, PD-L1 programmed death-ligand 1, CTLs cytotoxic T cells, IFN interferon, Tregs regulatory T cells, TME tumor microenvironment, MDSC myeloid-derived suppressor cells, OS overall survival, FOXP3 Forkhead box protein P3